Mizuho analyst Anthony Petrone initiated coverage of Boston Scientific with a Neutral rating and $52 price target. The analyst believes Boston Scientific’s portfolio mix toward critical care products "should be a safe recession hedge." However, he views the stock’s valuation as full at current levels.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific resumed with a Buy at Citi
- Boston Scientific Snaps up a Stake in Acotec
- Boston Scientific to acquire majority stake of Acotec Scientific
- Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
- Boston Scientific price target raised to $54 from $48 at Raymond James
